China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance from the National Medical Products Administration (NMPA) for its investigational drugs HB0028 and HB002.1T. The drugs are set to enter clinical studies, either in combination with or without standard chemotherapy, for the treatment of advanced solid tumors.
HB0028: A Dual-Targeting Bispecific Antibody
HB0028 is a bispecific antibody (BsAb) that targets both programmed-death 1 (PD-1) and transforming growth factor-β (TGF-β). Currently in Phase I clinical stage, this innovative therapy aims to enhance the immune response against cancer cells by simultaneously blocking two critical pathways involved in tumor growth and immune evasion.
HB002.1T: A VEGFR-Targeted Fusion Protein
HB002.1T is a vascular endothelial growth factor receptor (VEGFR)-targeted fusion protein designed to treat advanced solid tumors. This drug differentiates itself from bevacizumab in terms of molecule design and pre-clinical pharmacological efficacy. It has demonstrated a wide safety window, long half-life, and preliminary active anti-tumor therapeutic signals in Phase Ia studies. These attributes make it a promising candidate for improving treatment outcomes in patients with advanced solid tumors.-Fineline Info & Tech
